UB Paderborn / Katalog / Suche / in CDI

1 – 25 von 397

Sortiert nach

MET Exon 14 Alterations in Lung Cancer: Exon Skipping Extends Half-Life

Clinical cancer research, 2016-06, Vol.22 (12), p.2832-2834

Drilon, Alexander

2016

Link zum Volltext

Verfügbarkeit prüfen

NTRK fusion-positive cancers and TRK inhibitor therapy

Nature reviews. Clinical oncology, 2018-12, Vol.15 (12), p.731-747

2018

Link zum Volltext

Verfügbarkeit prüfen

MET-dependent solid tumours - molecular diagnosis and targeted therapy

Nature reviews. Clinical oncology, 2020-09, Vol.17 (9), p.569-587

2020

Link zum Volltext

Verfügbarkeit prüfen

State-of-the-Art Strategies for Targeting RET -Dependent Cancers

Journal of clinical oncology, 2020-04, Vol.38 (11), p.1209-1221

2020

Link zum Volltext

Verfügbarkeit prüfen

ROS1-dependent cancers - biology, diagnostics and therapeutics

Nature reviews. Clinical oncology, 2021-01, Vol.18 (1), p.35-55

2021

Link zum Volltext

Verfügbarkeit prüfen

Antitumor activity of crizotinib in lung cancers harboring a MET exon 14 alteration

Nature medicine, 2020-01, Vol.26 (1), p.47-51

2020

Link zum Volltext

Verfügbarkeit prüfen

Next-Generation Sequencing of Pulmonary Large Cell Neuroendocrine Carcinoma Reveals Small Cell Carcinoma-like and Non-Small Cell Carcinoma-like Subsets

Clinical cancer research, 2016-07, Vol.22 (14), p.3618-3629

2016

Link zum Volltext

Verfügbarkeit prüfen

RASA1 and NF1 are Preferentially Co-Mutated and Define A Distinct Genetic Subset of Smoking-Associated Non-Small Cell Lung Carcinomas Sensitive to MEK Inhibition

Clinical cancer research, 2018-03, Vol.24 (6), p.1436-1447

2018

Link zum Volltext

Verfügbarkeit prüfen

Optimizing the sequencing of tyrosine kinase inhibitors (TKIs) in epidermal growth factor receptor (EGFR) mutation-positive non-small cell lung cancer (NSCLC)

Lung cancer (Amsterdam, Netherlands), 2019-11, Vol.137, p.113-122

2019

Link zum Volltext

Verfügbarkeit prüfen

Squamous-cell carcinomas of the lung: emerging biology, controversies, and the promise of targeted therapy

The lancet oncology, 2012-10, Vol.13 (10), p.e418-e426

2012

Link zum Volltext

Verfügbarkeit prüfen

Targeted therapy outcomes in RET -rearranged lung cancers: drug or driver?

The lancet respiratory medicine, 2017-01, Vol.5 (1), p.5-6

Drilon, Alexander

2017

Link zum Volltext

Verfügbarkeit prüfen

NTRK fusion detection across multiple assays and 33,997 cases: diagnostic implications and pitfalls

Modern pathology, 2020-01, Vol.33 (1), p.38-46

2020

Link zum Volltext

Verfügbarkeit prüfen

Pan-Trk Immunohistochemistry Is an Efficient and Reliable Screen for the Detection of NTRK Fusions

The American journal of surgical pathology, 2017-11, Vol.41 (11), p.1547-1551

2017

Link zum Volltext

Verfügbarkeit prüfen

The evolution of RET inhibitor resistance in RET-driven lung and thyroid cancers

Nature communications, 2022-03, Vol.13 (1), p.1450-1450, Article 1450

2022

Link zum Volltext

Verfügbarkeit prüfen

Targeting RET-driven cancers: lessons from evolving preclinical and clinical landscapes

Nature reviews. Clinical oncology, 2018-03, Vol.15 (3), p.151-167

2018

Link zum Volltext

Verfügbarkeit prüfen

Expanding the Molecular Characterization of Thoracic Inflammatory Myofibroblastic Tumors beyond ALK Gene Rearrangements

Journal of thoracic oncology, 2019-05, Vol.14 (5), p.825-834

2019

Link zum Volltext

Verfügbarkeit prüfen

Cabozantinib in patients with advanced RET -rearranged non-small-cell lung cancer: an open-label, single-centre, phase 2, single-arm trial

The lancet oncology, 2016-12, Vol.17 (12), p.1653-1660

2016

Link zum Volltext

Verfügbarkeit prüfen

Organizing precision medicine: A case study of Memorial Sloan Kettering Cancer Center's engagement in/with genomics

Social science & medicine (1982), 2023-05, Vol.324, p.115789-115789, Article 115789

2023

Link zum Volltext

Verfügbarkeit prüfen

Decision‐making as discovery: Vetting clinical research in a leading precision oncology service

Sociology of health & illness, 2024-03, Vol.46 (3), p.495-513

2024

Link zum Volltext

Verfügbarkeit prüfen

MET IHC Is a Poor Screen for MET Amplification or MET Exon 14 Mutations in Lung Adenocarcinomas: Data from a Tri-Institutional Cohort of the Lung Cancer Mutation Consortium

Journal of thoracic oncology, 2019-09, Vol.14 (9), p.1666-1671

2019

Link zum Volltext

Verfügbarkeit prüfen

Colorectal Carcinomas Containing Hypermethylated MLH1 Promoter and Wild-Type BRAF/KRAS Are Enriched for Targetable Kinase Fusions

Cancer research (Chicago, Ill.), 2019-03, Vol.79 (6), p.1047-1053

2019

Link zum Volltext

Verfügbarkeit prüfen

Immunogenicity and therapeutic targeting of a public neoantigen derived from mutated PIK3CA

Nature medicine, 2022-05, Vol.28 (5), p.946-957

2022

Link zum Volltext

Verfügbarkeit prüfen

1 – 25 von 397

Suche als RSS-Feed

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(369)
Mit Volltextzugriff
(365)

Publikationsform

Sprache

Erscheinungsjahr

n.n

Thema

Science & Technology
(169)
Life Sciences & Biomedicine
(162)
Humans
(152)
Oncology
(150)
Mutation
(68)
Female
(67)
Lung Neoplasms - Drug Therapy
(63)
Lung Neoplasms - Genetics
(61)
Male
(58)
Middle Aged
(55)
Aged
(52)
Adult
(46)
Carcinoma, Non-Small-Cell Lung - Drug Therapy
(44)
Patients
(39)
Tumors
(38)
Aged, 80 And Over
(36)
Protein Kinase Inhibitors - Therapeutic Use
(35)
Lung Cancer
(34)
Neoplasms - Drug Therapy
(33)
Respiratory System
(31)

15 weitere anzeigen...

Weniger anzeigen...

Zeitschrift / Serie

5 weitere anzeigen...

Weniger anzeigen...

Neu hinzugefügt

... seit 7 Tagen
(1)
... seit 90 Tagen
(4)

Menü

Weitere Dienste

Einstellungen

MET Exon 14 Alterations in Lung Cancer: Exon Skipping Extends Half-Life

NTRK fusion-positive cancers and TRK inhibitor therapy

MET-dependent solid tumours - molecular diagnosis and targeted therapy

State-of-the-Art Strategies for Targeting RET -Dependent Cancers

ROS1-dependent cancers - biology, diagnostics and therapeutics

Antitumor activity of crizotinib in lung cancers harboring a MET exon 14 alteration

Next-Generation Sequencing of Pulmonary Large Cell Neuroendocrine Carcinoma Reveals Small Cell Carcinoma-like and Non-Small Cell Carcinoma-like Subsets

RASA1 and NF1 are Preferentially Co-Mutated and Define A Distinct Genetic Subset of Smoking-Associated Non-Small Cell Lung Carcinomas Sensitive to MEK Inhibition

Optimizing the sequencing of tyrosine kinase inhibitors (TKIs) in epidermal growth factor receptor (EGFR) mutation-positive non-small cell lung cancer (NSCLC)

Squamous-cell carcinomas of the lung: emerging biology, controversies, and the promise of targeted therapy

Targeted therapy outcomes in RET -rearranged lung cancers: drug or driver?

NTRK fusion detection across multiple assays and 33,997 cases: diagnostic implications and pitfalls

Pan-Trk Immunohistochemistry Is an Efficient and Reliable Screen for the Detection of NTRK Fusions

The evolution of RET inhibitor resistance in RET-driven lung and thyroid cancers

Targeting RET-driven cancers: lessons from evolving preclinical and clinical landscapes

Expanding the Molecular Characterization of Thoracic Inflammatory Myofibroblastic Tumors beyond ALK Gene Rearrangements

Cabozantinib in patients with advanced RET -rearranged non-small-cell lung cancer: an open-label, single-centre, phase 2, single-arm trial

Organizing precision medicine: A case study of Memorial Sloan Kettering Cancer Center's engagement in/with genomics

Safety and Antitumor Activity of the Multitargeted Pan-TRK, ROS1, and ALK Inhibitor Entrectinib: Combined Results from Two Phase I Trials (ALKA-372-001 and STARTRK-1)

RET Solvent Front Mutations Mediate Acquired Resistance to Selective RET Inhibition in RET-Driven Malignancies

Decision‐making as discovery: Vetting clinical research in a leading precision oncology service

MET IHC Is a Poor Screen for MET Amplification or MET Exon 14 Mutations in Lung Adenocarcinomas: Data from a Tri-Institutional Cohort of the Lung Cancer Mutation Consortium

Colorectal Carcinomas Containing Hypermethylated MLH1 Promoter and Wild-Type BRAF/KRAS Are Enriched for Targetable Kinase Fusions

Prospective Comprehensive Molecular Characterization of Lung Adenocarcinomas for Efficient Patient Matching to Approved and Emerging Therapies

Immunogenicity and therapeutic targeting of a public neoantigen derived from mutated PIK3CA

Suchergebnisse filtern